INTRODUCTION
Metabolic syndrome (MetS) is a complex metabolic condition involving abnormal adipose deposition and function, dyslipidemia, and hyperglycemia. Insulin resistance (IR) is the main pathologic characteristic of MetS and the most accepted unifying theory explaining the pathophysiology of the disease. 1 In the search for improved and novel therapeutic strategies, microRNAs (miRNAs) have drawn attention as potential targets due to their regulatory role on gene networks involved in metabolism, including lipid and glucose homeostasis. 2 Mounting evidence suggests that circulating miRNAs are involved in the regulation of obesity, diabetes, and MetS, but existing studies have yielded inconclusive results. 3, 4 Recently, Ortega et al revealed plasma miR-142-3p, miR-140-5p, miR-15a, miR-520c-3p, and miR-423-5p levels to be novel biomarkers for risk estimation and classification of morbidly obese patients. 5 In a subsequent study, Pescador et al supported the usage of serum miR-138, miR-15b, and miR-376a levels as valuable predictive biomarkers of obesity. 6 Examining the associations of circulating miRNAs levels with MetS and insulin sensitivity in humans may lead to improved insight into the pathophysiology of this condition.
Previous studies reported miR-143-3p expression to be dysregulated in db/db mice, diet-induced obese, and diabetic mice as well as human patients. 7 Studies addressing the role of miR-143-3p in adipose tissue by gain-or loss-of-function approaches provided evidence for an adipocyte differentiation-promoting effect of miR-143-3p in vitro. 8 Studies concerning miR-143-3p deficient mice revealed it to be indispensable for adipose-tissue formation and maintenance in vivo. Increased hepatic miR-143-3p expression in 2 different mouse models of obesity and the discovery that miR-143-3p affects hepatic insulin action and systemic glucose homeostasis in vivo, as independently demonstrated by overexpression and knockout mouse models, define miR-143-3p as an integrator of metabolic signaling. 9 This provides functional evidence for a role of altered post-transcriptional gene silencing in the development of obesity-associated insulin resistance in vivo.
Recently, mRNAs and miRNAs have been identified in exosomes. Their ingestion by neighboring or distant cells may result in subsequent modulation of a variety of cytological functions. 10 This phenomenon suggests the existence of an active exosomal miRNA sorting mechanism, since the miRNA profiles of exosomes may differ from those of parent cells. 11 Exosomal miRNAs play an important role in disease progression. The discovery of circulating miRNAs points to the likelihood of their involvement in facilitating metabolic crosstalk between organs, as well as serving as novel biomarkers for a variety of diseases. 12 An unconventional role of miRNA in neurodegeneration was described in the activation of Toll-like receptor 7 by let-7. 13 However, the physiological relevance of dysregulated circulating miR-143-3p expression in obesity has remained elusive. In the present study, we analyzed circulating miRNA expression patterns in a MetS cohort as well as in obese (diet-induced) insulin resistant mice, and validated the functional role played by and mechanistic involvement of altered circulating miR-143-3p on insulin signaling, both in vivo and in vitro.
MATERIALS AND METHODS
Cross-sectional study subjects. Random 1:1 pairing of 50 MetS patients and 50 controls was performed. Subjects were selected from a population based cross-sectional survey, which was conducted from March to May 2010 in the Caihe community of Hangzhou, Zhejiang province, China, as previous reported.
14 Briefly, a total of 624 eligible Han Chinese participants, aged 40À65 years, were recruited in the baseline study. MetS was defined according to standards generated by the joint committee for developing chinese guidelines on prevention and treatment of dyslipidemia in adults (JCDCG). 15 The study protocol was approved by the Ethics Committee of Sir Run Run Shaw Hospital and all patients provided informed consent.
Circulating microarray. Genome-wide circulating miRNA profiles were detected via microarray (Serum/ Plasma Focus microRNA PCR Panel, V1.M, Exiqon) in serum samples from 4 patients with MetS and 4 controls. Comprehensive coverage of Sanger miRBase v14 was enabled across a 2-card set of TaqMan Array MicroRNA Cards, resulting in a total of 377 unique assays specific to human miRNAs. A total of 2 mixtures were shipped on dry ice to KangCheng Bio-tech Inc. (Shanghai, China), which completed the miRNA microarrays, according to manufacturer instructions.
Animals and animal treatments. All animal care procedures and methods were performed in accordance with the guidelines of the Animal Care Committee of Zhejiang University. Male C57BL/6 mice (aged 8 weeks) were purchased from Slack Experimental Animal Center of the Chinese Academy of Sciences (Shanghai, China). A cohort of 20 mice were housed singly and maintained on a 12hour light-dark cycle. Mice were weighed and divided into 2 groups: 5 into a normal-chow diet group (NCD group; carbohydrate, 63.92%; protein, 26.18%; fat, 9.9%) and 15 into a high-fat diet group (HFD group; 35% carbohydrate, 20% protein and 45% fat; Research Diets, NJ; 10 of which were treated with antagomirs) for 12 weeks. After 8 weeks of maintenance on either a NCD or HFD, an intraperitoneal glucose tolerance test (GTT) was performed after an overnight fast of the animals. After 10 weeks, an intraperitoneal insulin tolerance test (ITT) was performed after a 4hour fast. After 12 weeks, their body weights were measured, then mice were sacrificed by cervical dislocation after exsanguination. For the other 10 HFD-induced obese mice, antagomirs were administered twice weekly via tail vein injection for another 2 weeks (50 mg/kg body weight), the GTT and ITT were performed again as mentioned above.
GTT and ITT. For the GTT, mice were fasted overnight and then injected intraperitoneally with 1.5 g/kg glucose. Blood glucose levels were measured from tail blood using One Touch Ultra glucose strips (LifeScan, Pennyslvania) at predetermined time points (0 minute, 15 minutes, 30 minutes, 60 minutes, and 120 minutes). For the ITT, mice were fasted for 4 hour and injected intraperitoneally with 0.5 U/kg insulin (Eli Lilly Company), and blood glucose levels were measured at predetermined time points using the above methodology.
Plasma lipid and lipoprotein determination. Total cholesterol (CHO) and triglyceride (TG) concentrations were measured by using the cholesterol oxidase phenol 4-aminoantipyrine peroxidase method (CH201, Randox) and glycerol phosphate oxidase-p-amino phenazone methods (TR1697, Randox). High-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c) concentrations were measured by using the clearance method (CH2652 and CH2657, Randox).
Culture and differentiation of 3T3-L1 preadipocytes.
3T3-L1 preadipocytes and 293HEK cells were purchased from the American Type Culture Collection (ATCC). They were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS, Bio-rad) and 100 IU/ml penicillin/streptomycin at 37˚C, 5% CO 2 . Two days postconfluence, 3T3-L1 cells (designated as Day 0) were induced to differentiate into adipocytes via addition of differentiation mixture with DMEM containing 10% FBS, 10 mg/ml insulin (TOCRIS), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX, Sigma) and 1mM dexamethasone (Sigma). Two days later, culture medium was changed to DMEM supplemented with 10% FBS and 10 mg/ml insulin for 2 days. Medium was subsequently replaced every other day with DMEM containing 10% FBS for different periods until day 10.
Treatment with agomirs and antagomirs. The cholesterol-conjugated 2 0 -O-methyl-modified mimic (agomir-143-3p), agomir-NC, antagomir-143-3p, and antagomir-NC were synthesized by RiboBio (RiboBio, Guangzhou, China). HFD-induced obese mice were administered either the miR-143-3p antagomirs (antagomir-143-3p) or control antagomirs (antagomir-NC) twice weekly via tail vein injection for 2 weeks (50 mg/kg body weight). When 3T3-L1 cells were approximately 30%À40% confluent, either agomir-143-3p (100 nM) or antagomir-143-3p (200 nM), as well as matched controls, were treated. Cells were subsequently harvested after 48hour or 72hour and re-treated every 2 days throughout the process of induction of differentiation.
Glucose uptake measurement by flow cytometry.
Glucose uptake activity was measured using a fluorescent D-glucose analogue 2-[N-(7-nitrobenz-2-oxa-1,
Briefly, differentiated 3T3-L1 cells in 12-well plates were treated with agomirs and antagomirs for 48 hour. Cells were incubated with 100 nM insulin in glucose-free DMEM for 10 minutes, 60 mM 2-NBDG was added to the medium for another 1 hour. Fluorescence activity was subsequently determined by FACScalibur flow cytometry (Becton Dickinson, Franklin Lakes) according to manufacturer instructions.
Oil red O staining. Ten days after induction of 3T3-L1 preadipocyte differentiation, cells were washed twice in D-Hank's solution, fixed in 4% formaldehyde for 30 minutes, and washed thrice with water. Then, cells were stained with Oil Red O (Sigma) for 15 minutes. Following 3 washes in water, lipid droplets were observed and photographed under a microscope (TE2000-E; Nikon, Japan).
Serum and urine miRNA detection. Total RNA was extracted from serum using a miRNeasy kit (Qiagen). Total RNA was extracted from urine using Trizol LS reagent (Invitrogen) and purified using a Urine RNA Purification Kit (Abnova). A miDETECT A Track miRNA qualitative real time-polymerase chain reaction (qRT-PCR) Start Kit (RiboBio, Guangzhou, China) was used for validating expression of microRNAs by poly(A) tailing-based RT-PCR, adhering to manufacturer directions. According to microarray results, miR-423-5p and miR-93-5p, as well as U6, were selected as stable endogenous control miRNAs. miRNA qPCR Primer sets were purchased from Guangzhou RiboBio Co. (Guangzhou, China).
RNA extraction and mRNA quantitative real-time PCR.
Total RNA was isolated from treated cells with the Trizol reagent (Invitrogen) and reverse-transcribed using a reverse transcription reagents kit (TaKaRa) to generate a cDNA template. Real-time quantitative PCR was performed using a PCR kit containing SYBR Green (TaKaRa) and a 7500 real-time PCR detection system (Applied Biosystems). Relative expression was normalized to that of glyceraldehyde 3-phosphate dehydrogenase as an internal control for quantification of individual mRNA species and calculated using the formula 2 ¡DDCt . Primer sets are listed in Supplementary Table VI. Western blotting. Equal amounts of protein (50 mg) denatured by boiling were separated by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis, transferred to Immun-Blot PVDF membranes (Millipore) and blocked with 5% nonfat milk for 1 hour at room temperature. Membranes were then incubated with primary antibodies (diluted 1:1000) including anti-rabbit phosphorylated AKT, AKT, anti-rabbit insulin-like growth factor 2 receptor (IGF2R) (Cell Signaling Technology, 1:1000), anti-rabbit insulin-like growth factor binding protein 5 (IGFBP5) (Proteintech, 1:1000), and anti-mouse b-actin (Sigma-Aldrich, 1:5000) at 4˚C overnight. After incubation with horseradish peroxidase-conjugated goat anti-rabbit/mouse secondary antibodies at room temperature for 1hour, immunoreactive proteins were detected using a chemiluminescent ECL assay kit (Millipore)
Dual-luciferase reporter assays. Homo sapiens IGF2R (Gene ID: 3482) and Homo sapiens IGFBP5 (Gene ID: 3488) 3 0 untranslated regions (3 0 UTRs) containing predicted miR-143-3p binding sites were amplified via PCR and cloned into the XhoI/HindIII site of a pGL4-basic vector (Promega) to generate the pGL4-IGF2R-3 0 UTR and pGL4-IGF2R-3 0 UTR vectors. 293HEK cells (5 £ 10 4 ) were seeded in 24-well plates 24 hour before transfection. The 100 ngÀ1mg of construct plasmids along with 200 ng of the Renilla luciferase plasmid (pRL-TK, considered as an internal control) were cotransfected using Lipofectamine 2000 (Invitrogen). Cells were harvested and assayed for luciferase activity using the dual-luciferase reporter assay system (Promega), the luciferase activities were normalized to the cotransfected pRL-TK plasmid. Primer sets are listed in Supplementary Table VI. Statistical analysis. For the cross-sectional study, all continuous variables were tested for a normal distribution. Normally distributed variables were expressed as mean § SD. Variables with a skewed distribution were presented with a median (interquartile range, 25%À75%). Categorical variables were presented as frequencies and percentages. Differences of baseline characteristics between participants with and without MetS were analyzed via t-test for continuous variables and via chi-square test for categorical variables. Correlations were obtained via Spearman correlation analysis in the cross-sectional study. Incidence of MetS at different levels of serum or urine miR-143-3p was analyzed by the Chi-square. Logistic regression and multiple stepwise regression analyses were conducted in the prospective study to evaluate what influences variables exert on MetS risks. SPSS 17.0 (IBM) was used for statistical analyses. A significant difference was defined as P < 0.05.
RESULTS
Expression of circulating miR-143-3p is associated with insulin resistance and upregulated in MetS. Serum samples were obtained from 4 patients with MetS and 4 nondiseased controls (non-MetS), enabled across a total of 377 unique assays specific to human miRNAs. Of these 377 miRNAs, 27 were screened out as differentially expressed in the sera of MetS patients compared to control subjects via microarray with a fold change > 2 (P < 0.05) (Fig 1A and B, Supplementary Table I ). Among these, 6 prominently expressed miRNAs (miR-20a-3p, miR-143-3p, miR-365a-3p, miR-29a-3p, let-7i-5p, and miR-99a-5p) were selected for further validation from larger, independent individual serum and urine samples from 50 MetS patients (52.0% men) and 50 control subjects (48.0% men) by RT-qPCR. Clinical characteristics of the study participants included in the validation study are shown in Supplementary Table II. Further qRT-PCR analysis confirmed that circulating miR-143-3p was increased significantly in MetS compared with controls both in serum and urine samples (P < 0.01) (Fig 1C) .
Associations between circulating miR-143-3p levels and parameters related to adiposity, insulin resistance, lipid profiles, and hepatic enzyme function were further assessed. Spearman correlation analyses of serum and urine miR-143-3p levels with metabolic risk were performed. Correlations between circulating miR-143-3p levels and metabolic parameters were noted to be at baseline (Supplementary  Table III , IV), while serum and urine miR-143-3p levels were correlated with the homeostatic model assessment of insulin resistance (HOMA-IR). The relevant indices for serum and urine miR-143-3p were determined to be R 2 = 0.4999 and R 2 = 0.2713 respectively, both P < 0.01 (Fig 2A and B) . Higher serum and urine miR-143-3p levels were accompanied by an increasing trend in the HOMA-IR and also correlated with a high density lipoprotein-cholesterol (HDL-c) ratio and percentage of body fat (Fat %), all P < 0.001 (Supplementary TableIII, IV).
We further assessed whether a high level of serum and urine miR-143-3p could also effectively predict the risk of developing insulin resistance in MetS. Multiple stepwise regression analysis using serum or urine miR-143-3p levels as a dependent variable after adjusting for gender, age, smoking and drinking revealed that serum and urine miR-143-3p levels were independently related to the HOMA-IR, HDL-c levels and waist circumference (WC); standardized b = 0.705, 0.292, and À0.174 for serum miR-143-3p, respectively, and standardized b = 0.856, 0.178, and À0.272 for urine miR-143-3p, respectively; all P < 0.05 (Supplementary TableV). After controlling for confounding factors, miR-143-3p was determined to be an independent risk factor for insulin resistance; odds ratio (OR) = 15.500, 95% confidence interval (CI) = 1.329À24.93 for serum miR-143-3p levels, and OR = 3.225, 95% CI = 1.073À9.687 for urine miR-143-3p levels, both P < 0.001 (Fig 2C) . The incidence of MetS in participants with a high miR-143-3p level was 6.612 (serum miR-143-3p level) and 3.160 (urine miR-143-3p level) times higher in MetS compared to those with low miR-143-3p levels after adjusting for age, gender, smoking, and drinking status (Fig 2C) .
Downregulation of circulating miR-143-3p prevents obesity-induced insulin resistance, glucose tolerance, and dyslipidemia. Population analysis data revealed an elevated circulating miR-143-3p level to have a positive association with MetS and insulin resistance. To identify possible roles miR-143-3p plays in metabolic regulation and its potential contributions to the development of obesity associated disturbances in insulin resistance, we first fed a HFD to a group of mice for 12 weeks, utilizing mice fed a standard NCD as a control. The HFD mice underwent an increase in their total body weight compared with NCD mice (29.34 § 1.76g of HFD mice vs 24.48 § 2.71 g of NCD mice, P < 0.01) (Supplementary Fig 1A) . On histological evaluation, we observed that the number of hypertrophied adipocytes increased in HFD mice (Supplementary Fig 1B) . Furthermore, HFD mice had a significantly more blunted glucose tolerance and insulin sensitivity than NCD controls, as determined by glucose tolerance test (GTT) and insulin tolerance test (ITT), respectively. These findings suggested the presence of insulin resistance in HFD mice ( Supplementary Fig 1C and D) .
We next evaluated the expression of circulating miR-143-3p in the serum of an HFD mouse model. Our findings revealed a significant Elevated expression of circulating miR-143-3p was associated with insulin resistance in MetS patients compared to control subjects. (A) Spearman correlation analyses of serum miR-143-3p levels with homeostasis model assessment of insulin resistance (HOMA-IR) were performed; n = 100, P < 0.01. (B) Spearman correlation analyses of urine miR-143-3p levels with HOMA-IR were performed; n = 100, P < 0.01. (C) Multiple stepwise logistic regression analysis of MetS, HOMA-IR, and other metabolic subgroups (Central obesity, hypertension, hyperglycemia, hypertriglyceridemia, and low HDL-c) associated with serum and urine miR-143-3p levels.
9.18-fold upregulation of miR-143-3p expression in the serum of HFD mice as compared with NCD mice (P < 0.01) (Fig 3A) . To address whether altered expression of miR-143-p was restricted to the serum of obese mice, we next determined its expression in various organs of obese mice as compared with control mice. This analysis revealed significant upregulation of miR-143-3p in the heart, skeletal muscle and pancreas of obese mice, whereas, its expression was significantly reduced in inguinal white adipose tissue (iWAT) and epididymal white adipose tissue (eWAT) (P < 0.05) (Fig 3B) . Thus, miR-143-3p seems upregulated in tissues targeted by insulin.
To investigate whether increased circulating miR-143-3p expression contributes to insulin sensitivity, we injected the miR-143-3p antagomir into the tail vein of HFD mice to knockdown miR-143-3p expression. Obese mice treated in the presence of antagomir-143-3p consistently displayed about a 40% reduction in miR-143-3p levels compared with antagomir-NC treated obese mice (P < 0.01) (Fig 3C) . Furthermore, GTTs revealed antagomir-143-3p treated obese mice to have significantly better glucose tolerance than antagomir-NC treated obese mice (Fig 3D) . ITT analysis revealed that insulin resistance was also significantly ameliorated in the antagomir-143-3p treated group (Fig 3E) . Hematoxylin/Eosin staining of white adipose tissues revealed that mice treated with antagomir-143-3p had smaller size of adipocytes in iWAT and eWAT (Fig 3F) , but there were no remarkable changes in the body weight as well as the weight of white adipose tissues in obese mice after treatment of antagomir-143-3p (Fig 3G) .
Then we further analyzed the plasma CHO, TG, HDL-c, and LDL-c levels after treatment with antagomir-143-3p (n = 4) as compared those treated with antagomir-NC (n = 4) to detect the effect of antagomir-143-3p in dyslipidemia induced by obesity in mice, the plasma CHO and TG levels reduced and the HDL-c level increased in the antagomir-143-3p treated group, the results demonstrated that downregulation of circulating miR-143-3p prevents obesity-induced lipid accumulation (Fig 3H) . The additional Oil Red O staining assay in differentiated 3T3-L1 cells treated with either agomir-143-3p or antagomir-143-3p also revealed that overexpression of miR-143-3p increased the lipidosis in differentiated 3T3-L1 cells, and the lipidosis decreased, while miR-143-3p downregulated, which was consistent with the above plasma lipid and lipoprotein detection (Fig 3I) .
MiR-143-3p overexpression impairs insulin-stimulated AKT activation and glucose uptake in 3T3-L1 preadipocytes. As shown above, downregulation of circulating miR-143-3p prevents obesity-induced insulin resistance, glucose tolerance and lipid accumulation. To further explore these findings, we directly assessed the effect of miR-143-3p on insulin signaling and glucose uptake in 3T3-L1 preadipocytes stimulated with insulin. Effects exerted by agomir-143-3p and antagomir-143-3p were evaluated by qRT-PCR assay. A 12.10-fold increase and 0.56-fold decrease in miR-143-3p expression, respectively, both P < 0.01 (Fig 4A) . Next, a glucose uptake assay was performed using a fluorescent 2-NBDG screening system. Overexpression of miR-143-3p significantly reduced insulin-stimulated 2-NBDG uptake in 3T3-L1 preadipocytes. Conversely, knockdown of miR-143-3p resulted in greater insulin-stimulated 2-NBDG uptake in this same cell type, P < 0.05 (Fig 4B and C) . Consistent with our results from the glucose uptake assay, overexpression of miR-143-3p reduced insulin-stimulated phosphorylation of AKT, while miR-143-3p knockdown increased AKT phosphorylation after insulin stimulation in 3T3-L1 preadipocytes (Fig 4D) .
Together, these results demonstrate that overexpression of miR-143-3p impairs insulin sensitivity.
IGF2R identified as among miR-143-3p target genes. To identify the molecular targets of miR-143-3p in the development of insulin resistance, we performed gene ontology and biological association analyses using the Database for Annotation, Visualization and Integrated Discovery (DAVID) Bioinformatics Resources 16 and searched for enrichment of specific target genes associated with insulin signaling, as well as glucose and lipid metabolism (Fig 5A) . After extensively searching three widely used bioinformatics databases (Miranda, Mirbase, and Targetscan), we determined that the IGF2R and IGFBP5 were 2 previously unidentified targets of miR-143-3p (Fig 5B) .
In agreement with prior detailed studies of the IGF insulin signaling system, 17 we detected mRNA expression of IGF1, IGF2, IGF1R, IGF2R and IGFBP5 after overexpression of miR-143-3p by cell treatment with agomirs. IGF2R (52.88% reduction, P < 0.01) and IGFBP5 (36.88% reduction, P < 0.05) levels were reduced by agomir-143-3p treatment (Fig 5C) . Protein levels of IGF2R and IGFBP5 were further confirmed to be downregulated by agomir-143-3p treatment and upregulated by antagomir-143-3p treatment as compared to treatment with controls by Western blot assay (Fig 5D) . We subsequently generated reporter constructs in which the luciferase coding sequence was fused to the 3 0 untranslated regions (UTRs) of IGF2R and IGFBP5. The dual-reporter luciferase assay revealed miR-143-3p to markedly repress luciferase activity of the IGF2R (48.97% reduction, P < 0.01) and IGFBP5 (40.04% reduction, P < 0.05) constructs as compared with a pGL4-basic vector (Fig 5E) , suggesting that IGF2R (and/or IGFBP5) was a direct target of miR-143-3p.
DISCUSSION
Our findings of circulating miR-143-3p level overexpression in HFD induced obese mice is consistent with prior studies describing miR-143-3p as being upregulated in tissues of ob/ob or db/db mice, as well as diet-induced obese and diabetic mice.
7À9,18 Sabine D. Jordan et al have reported increased hepatic miR-143-3p expression in 2 different mouse models of obesity, as well as miR-143-3p affecting hepatic insulin action and systemic glucose homeostasis in vivo. 7 Our present study further provides evidence that the overexpression of miR-143-3p impairs insulin-stimulated AKT activation and glucose uptake in 3T3-L1 preadipocytes. Further clinical evidence is necessary to explore the relevance of circulating miR-143-3p levels in the development of insulin resistance.
Here, we revealed circulating miRNA profiles of MetS patients via microarray analysis and confirmed that circulating miR-143-3p was increased significantly in MetS patients compared with controls, both in serum and urine samples. Recently, Rui Wang et al reported that elevated circulating miRNA-122 is associated with obesity and insulin resistance in young adults, 19 Xiliang Du et al revealed that miR-125b overexpression impaired the insulin signaling pathway in HepG2 cells, L02c cells, and primary hepatocytes, 20 while, He Qing Fang et al showed that circulating miRNA-21 is downregulated in patients with MetS. 21 However, neither of these 2 miRNAs was detected in our present study. It remains unclear, whether differences in genetic background, diet composition or miRNAdetection methods account for the variable findings with respect to miRNA expression in different population cohorts. This might be owing to the different clinical characteristics of these studies and the lack of a generally accepted endogenous miRNA control to normalize for circulating miRNA levels.
Mammalian circulating miRNAs are packaged inside lipid or lipidprotein complexes, such as microvesicles, exosomes, or apoptotic bodies. 22 Specific miRNAs tend to be preferentially released by cells and are thus more prone to be found in circulation. 23, 24 Previous literature has unequivocally reported endogenous serum miRNAs to be sufficiently stable and quantifiable for reference as clinical biomarkers. [25] [26] [27] Mitchell et al found that the abundance of miRNAs in serum and plasma were strongly correlated. 28 Considering that clinical specimens of serum are more plentiful than plasma samples in many clinical sample repositories, serum samples would be suitable for investigations of miRNAs as blood-based biomarkers. 29 Thus, 1 important area of future research will be to investigate the potential prognostic value of a circulating miR-143-3p level for assessing survival of MetS patients. The findings of our study suggest a high level of serum and urine miR-143-3p to effectively predict an incident risk of MetS development.
In addition to the potential clinical biomarker function of serum miRNAs, Zavesky L et al demonstrated that assessment of urinary miRNA expression may be a feasible method of exploring the potential for identifying novel diagnostic and prognostic markers. 30 Here, we first revealed the urine miR-143-3p to be significantly increased in MetS patients as compared with controls. Convenient a source as urine might be for conducting clinical tests, using urine miRNA levels as a novel diagnostic tool remains challenging. This approach currently is in its early stages, and many technical issues, as well as procedure cost, stand in the way of popularization and widespread clinical application. /Akt) in each group, *P < 0.05, **P < 0.01 vs the absent-insulin group Our study also identified and confirmed 2 novel targets of miR-143-3p: IGF2R and IGFBP5. The ligands of the IGF system (insulin, IGF1, and IGF2) exert their biological effects by binding to the insulin receptor (IR), the type 1 IGF receptor (IGF-1R) and hybrids thereof. 31 Hybrid receptors of IGF1R and IR also bind IGFs. 32 Interestingly, our further findings revealed expression of miR-143-3p to be IGF2 dose-dependent; from 0 ng/ml to 100 ng/ml (Supplementary Fig 2C) . We also found miR-143-3p expression in 3T3-L1 preadipocytes treated with 100 ng/ml exogenous IGF2a to be IGF2 timedependent; as measured at different time points from 0 hour to 48hours (Supplementary Fig 2D) . These findings provide strong evidence for the role of miR-143-3p in IGF2 signaling, as the latter exerts its biological effects via binding to IGF2R, IGF1R and the A isoform of IR (IR-A). IGF2R also binds IGF2 to play a role in IGF2 clearance rather than signaling. 33 In addition, insulin stimulates translocation of IGF-2R to the cell surface, promoting IGF2 clearance. IGF2 may also increase glucose uptake into 3T3-L1 and human adipocytes, 34, 35 as we confirmed the miR-143-3p can.
IGFBP5, an inhibitory binding protein with affinity for IGF, is highly upregulated in nerve biopsies of patients with diabetic neuropathy. Zhang WR et al have showed that miR-143 regulates proliferation and differentiation of bovine skeletal muscle satellite cells by targeting IGFBP5, 36 miR-143 also directly regulates the expression of IGFBP5 during muscle regeneration. 37 No mechanism of action or function of IGFBP5 in insulin signaling and MetS patients was elucidated.
In summary, this study demonstrates the importance of circulating miR-143-3p in insulin signaling pathways of both MetS patients and HFD induced obese mice. Restoration of previously knocked-down circulating miR-143-3p contributes to the development of obesity-induced metabolic abnormalities. Conversely, downregulation of circulating miR-143-3p prevents obesity induced insulin resistance, glucose tolerance and lipid accumulation via regulation of the IGF2-IGF2R (and/or IGFBP5) pathway(s). These findings suggest that circulating miR-143-3p has potential as a promising novel target in the treatment of MetS and insulin resistance. 0 UTRs. Results represent 3 independent experiments. *P < 0.05, **P < 0.01.
